---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000165"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:54:58.529310+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Coherus terminates TIGIT program collaboration with Junshi Biosciences after portfolio review

## Summary
- Delivered notice of termination on January 10, 2024 for the TIGIT Program (CHS-006).
- Decision follows Surface Oncology acquisition and portfolio prioritization; agreement remains effective for LOQTORZI (toripalimab-tpzi).
- Coherus will continue to support patients in ongoing CHS-006 studies (NCT05061628, NCT05757492).
- Company believes termination is in its best interests; wind-down expected over coming months.

## SEC filing metadata
- accession: 0001558370-24-000165
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837024000165/0001558370-24-000165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837024000165/chrs-20240110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000165
- JSON: https://secwatch.observer/filing/0001558370-24-000165.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.